Week 5: July 21, 2010

Pharmacogenomics


Instructor:

Russ Altman, MD, PhD
Professor of Bioengineering, Genetics, and Medicine

Learning Objectives

  • Gain understanding of how genetics can help explain individual variation in drug response
  • Gain understanding of how a patient's genetics can affect the pharmacokinetics (PK genes) and pharmcodynamics (PD genes) of a drug
  • Become familiar with framework for evaluating the clinical utility of a pharmacogenomics association


    • Data Exercises (Instructions)

  • Estimating pharmacogenetic drug doses: warfarin genetic algorithm vs. clinical algorithm
  • Clopidogrel response via CYP2C19
  • Statin-induced myopathy risk via SLC01B1


    • Lecture Slides
    Data Exercise Results


    Readings

    1. International Warfarin Pharmacogenetics Consortium, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009 Feb 19;360(8):753-64. Erratum in: N Engl J Med. 2009 Oct 15;361(16):1613. Dosage error in article text.
    2. Supplement to IWPC et al. NEJM 2009 (with genetic and clinical algorithm)
    3. Sagreiya et al. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet Genomics. 2010 May 3. [Epub ahead of print]
    4. SEARCH Group. SLCO1B1 Variants and Statin-Induced Myopathy -- A Genomewide Study. New Engl J Med. 2008 Aug 21;359(8):789-99.